---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-057478"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:20:49.713036+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals appoints R. Keith Woods to Board of Directors

## Summary
- Appointed R. Keith Woods, former COO of argenx SE, to the Board effective December 7, 2023.
- Granted options to purchase 20,522 shares (3-year monthly vest) and 11,960 shares (1-year cliff vest).
- Woods has 30+ years biopharma experience; previously SVP North American operations at Alexion, managed $1B+ annual sales.
- No arrangements or family relationships disclosed; standard indemnification agreement.

## SEC filing metadata
- accession: 0001140361-23-057478
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036123057478/0001140361-23-057478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036123057478/ef20016480_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-057478
- JSON: https://secwatch.observer/filing/0001140361-23-057478.json
- Plain text: https://secwatch.observer/filing/0001140361-23-057478.txt

## Key facts
- Executive change
  R. Keith Woods was appointed as Director at ROCKET PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: appointed R. Keith Woods to the Board, effective December 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036123057478/0001140361-23-057478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.